NCT06181812Recruiting
Pathogenic Variants in Genes Associated With Lung Adenocarcinoma
Prevalence of Pathogenic or Likely Pathogenic Germline Variants in Cancer Predisposition Genes Among Patients With Lung Adenocarcinoma
Source: ClinicalTrials.gov · Last updated 8 Apr 2026
Brief summary (registry, in English)
The goal of this observational study is to describe the prevalence of germ line-pathogenic variants in Mexican patients with lung adenocarcinoma. The main questions it aims to answer are: 1. What is the prevalence of pathogenic variants in genes associated with lung adenocarcinoma in Mexican patients younger than fifty? 2. Which clinical-pathological characteristics are associated with germ-line pathogenic variants in patients with lung adenocarcinoma? 3. How actionable somatic mutations are associated with germ line-pathogenic variants of patients with lung adenocarcinoma? Participants will be asked to sign an informed consent; after that, they will be instructed to donate 10 ml of peripheral blood by venipuncture in the morning and before the patient has taken morning medication and the first meal, following a period of 8-12 hr fasting.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 332 (estimated)
- First submitted
- 13 Dec 2023
- Start date
- 15 Dec 2022
- Primary completion date
- 15 Dec 2026
- Lead sponsor
- Oscar Gerardo Arrieta Rodríguez
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT06181812
What you commit to
- Study type: Observational
- Planned participants: 332
- From 15 Dec 2022 to the primary completion date, 15 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- A sample of peripheral blood that is not accessible.
- Insufficient clinical pathological information in the electronic clinical record.
- Elimination Criteria:
- Withdrawal
- Insufficient DNA quality and quantity for genomic sequencing analyses.
- Lost of follow up
Who the study is looking for
- Both sexes
- ≥ 16 years old, according the institutional protocols for new patients admittances.
- histologically confirmed lung adenocarcinoma (LUAD)
- Signed written informed consent form
- A life expectancy greater than 8 weeks.
- Histologically confirmed LUAD and one of the following conditions: i) LCFH, defined as having one first-degree relative (FDR) or two or more second-degree relatives with LC, irrespective of the age at diagnosis. ii) Age at diagnosis ≤50 years, or ≤60 with a pack-years index. iii) Presence of ≥1 AGAs (EGFR, ALK, ROS1, KRAS, BRAF, MET exon 14 skipping, or RET).
Age in the registry: 16 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de Cancerología Coordinator of this site? Confirm its status | Mexico City | Mexico | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.